NICE rejects NHS funding Sanofi/Regeneron's Dupixent in asth...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

Takeda and Arcturus join hunt for coronavirus therapies

The Japanese drugs giant Takeda and the US biotech Arcturus Therapeutics have joined the hunt for therapies for the COVID-19 coronavirus.

Sanofi gets first OK for isatuximab for myeloma, challenging...

Chinese biotech censured for misleading coronavirus drug cla...

China’s BrightGene Bio-Medical Technology has been censured by the Shanghai Stock Exchange for wrongly claiming it is able to manufacture Gilead’s experimental drug remdesivir – scientists’

Sanofi’s Bozidar Jovicevic on how the company is approaching...

Paul Tunnah caught up with Sanofi’s vice president, global head of digital therapeutics at JP Morgan to talk about the landscape for digital health and the company’s plans for the space, in

Sanofi to combat shortages with European medicines ingredien...

Sanofi is to create a European company focused on production and marketing of active pharmaceutical ingredients (API) – the essential building blocks of medicines that are causing concerns